moneyheap
ANIP · Analysis updated Nov 10, 2026, 6:00 PM ET
Why is ANI Pharmaceuticals, Inc. (ANIP) stock moving?
ANIP reported a clear Q3 2026 beat: revenue of $290.8M vs. a $280.2M estimate and adjusted EPS of $2.70 vs. $2.18, with adjusted EBITDA of $83.3M. Management raised FY2026 adjusted EPS guidance to $9.37-$9.71 (consensus $9.26) and narrowed sales guidance to $1.085B-$1.125B, which lifted the low end but trimmed the top. The same day it announced a recommended offer of SEK 11.25 per share for Egetis Therapeutics, about $560M, to expand its rare disease business. Financing and closing terms are not detailed in the sources. The stock did not follow the beat: it hit a $76 intraday high on Nov 5 on 1.30M shares, then closed at $69.62, and kept falling to $67.41 on Nov 6 and $67.79 on Nov 9. On Nov 10 it rebounded 5.1% to $71.25 on 1.19M shares, roughly three times typical daily volume, and closed above its $70.34 VWAP. Analysts remain split: Guggenheim reiterated Buy with a $121 target, while Gary Nachman kept Hold with a $90 target. The fundamental news is positive, but the post-earnings sell-off and the Egetis deal's execution and funding remain open questions.
News behind the analysis
- ANI Pharmaceuticals Reports Third Quarter 2026 Financial Results and Updates GuidanceQ3 2026 revenue was $290.8M with adjusted non-GAAP EBITDA of $83.3M. The company narrowed full-year revenue guidance and raised its adjusted EBITDA and EPS outlook.
- ANI Pharmaceuticals Raises FY2026 Adj EPS Guidance from $9.19-$9.69 to $9.37-$9.71 vs $9.26 Est; Narrows FY2026 Sales Guidance from $1.080B-$1.140B to $1.085B-$1.125B vs $1.102B EstFull-year adjusted EPS guidance was raised to $9.37-$9.71, above the $9.26 consensus. Sales guidance was narrowed to $1.085B-$1.125B, against a $1.102B estimate.
- ANI Pharmaceuticals Q3 Adj. EPS $2.70 Beats $2.18 Estimate, Sales $290.800M Beat $280.196M EstimateQ3 adjusted EPS of $2.70 beat the $2.18 estimate, and sales of $290.8M beat the $280.2M estimate.
- ANI Pharmaceuticals Announces Recommended Public Offer to Acquire Egetis TherapeuticsThe company announced a recommended public offer of SEK 11.25 per share for Swedish biotech Egetis Therapeutics, valuing the deal at about $560M. The offer expands its rare disease business.
- ANI Pharmaceuticals Announces Offer At SEK 11.25 Per Share, About SEK 5.6B ($560M), To Acquire Egetis Therapeutics, Expanding Rare Disease BusinessThe SEK 11.25 per share offer for Egetis values the company at about SEK 5.6B ($560M). The move is framed as an expansion of ANI's rare disease business.
- ANI Pharmaceuticals Q3 2026 Earnings Call TranscriptThe transcript of the third-quarter 2026 earnings call, which followed the results release, is now available.
- Guggenheim Maintains Buy on ANI Pharmaceuticals, Raises Price Target to $121Guggenheim kept its Buy rating and lifted its price target to $121. The move follows the Q3 results and the Egetis offer.
- Analyst Gary Nachman Maintains Hold Rating on ANI PharmaceuticalsAnalyst Gary Nachman reaffirmed a Hold rating and kept a $90 price target. This is well below the Guggenheim target.
- Guggenheim Maintains Buy Rating and Raises Price Target for ANI PharmaceuticalsGuggenheim analyst Vamil Divan kept a Buy rating and raised the price target from $119 to $121.
About ANI Pharmaceuticals, Inc.
ANI Pharmaceuticals is a Princeton, New Jersey drugmaker that combines a fast-growing rare disease business with a large US generic drug operation. What sets it apart is Purified Cortrophin Gel, a prescription injectable (an ACTH drug) that is now its biggest product. The company is shifting toward rare disease, and in late 2026 it made an offer to buy Sweden's Egetis Therapeutics.
How it makes money
ANI sells prescription drugs, mostly in the US. Its main business is rare disease, led by Cortrophin Gel, which the company expects to bring in roughly $480–500 million in 2026. That is about 45% of its expected total sales of roughly $1.1 billion. The rare disease business also sells ILUVIEN, an eye implant for diabetic macular edema (about $80 million expected in 2026). Generic drugs bring in roughly $100 million a quarter, and a smaller share comes from established branded drugs and contract manufacturing.
What usually moves ANIP
- Cortrophin Gel sales growth, including its expansion into gout
- Payer and insurance coverage of high-cost specialty drugs
- Generic drug launches and pricing pressure
- Acquisitions such as the Egetis offer, plus debt levels
- Quarterly results against company guidance